PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's
PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.
Study identifier: NCT06151002. Status: RECRUITING.
Eligibility
Criteria: Inclusion Criteria: * Formal diagnosis of Parkinson Disease Exclusion Criteria: * Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI. * History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration) * Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease. * Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
- Minimum age: 18 Years
- Maximum age: 90 Years
Participating locations
- University College London (UCL), London
Study records are sourced from ClinicalTrials.gov. Confirm current eligibility, recruiting status, and locations in the official record.